GlassScriptPhysician profile
Kenneth H Shain
NPI 1083809255
$340,750.26
in general payments reported to CMS, 2019-2025
21 companies · $43K in 2025
The $43K reported for 2025 was more than what 94% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $72K · 2021: $31K · 2022: $58K · 2023: $25K · 2024: $36K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $96K · Food and Beverage: $6,795 · Travel and Lodging: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $96,024.75 |
| Food and Beverage | $6,795.20 |
| Travel and Lodging | $1,537.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $74,234.26 | 2019-2025 | |
| Janssen Biotech, INC. | $49,109.01 | 2019-2025 | Darzalex, Talvey, Carvykti |
| Celgene Corporation | $43,285.71 | 2019-2025 | Abecma, Pomalyst |
| Genzyme Corporation | $36,040.11 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $25,053.75 | 2020 | |
| Amgen INC. | $24,367.88 | 2019-2023 | Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $23,467.34 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $19,221.66 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $17,741.82 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $13,067.01 | 2020-2025 | Xpovio |
| Janssen Scientific Affairs, LLC | $7,111.41 | 2019-2025 | Tecvayli, Darzalex |
| Abbvie INC. | $3,037.88 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,781.00 | 2025 | |
| Janssen Research & Development, LLC | $902.87 | 2019 | |
| Legend Biotech USA INC. | $372.46 | 2024-2025 | Carvykti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $294.69 | 2021-2025 | Yescarta |
| Pfizer INC. | $245.09 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $160.23 | 2019-2022 | |
| Stemline Therapeutics INC. | $126.51 | 2019 | |
| Secura Bio, INC. | $101.50 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $28.07 | 2023 | Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Shain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.